Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Freund's adjuvant is an immunopotentiating agent comprised of mineral oil, emulsifier (mannide monooleate), and, in its complete form, heat-killed mycobacteria (usually Mycobacterium tuberculosis)[1][4][8]. There are two principal forms: Complete Freund’s Adjuvant (CFA), which includes mycobacteria, and Incomplete Freund’s Adjuvant (IFA), which lacks the mycobacterial component[1]. As a water-in-oil emulsion, the adjuvant retains antigen at the injection site and dramatically amplifies the immune response by inducing robust local inflammation, promoting recruitment and activation of antigen-presenting cells (e.g., macrophages), and resulting in potent activation of T helper cells and antibody production[1][3][4][5][9]. Due to severe inflammatory toxicity, its use is restricted to research in laboratory animals; it is not approved for use in humans[1][5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on freund's adjuvant.